跳至主要内容
临床试验/IRCT20220708055414N1
IRCT20220708055414N1
已完成
3 期

Evaluation Renoprotective Effect SGLT2 inhibitors on Prognosis of Transplant Kidney Patients

Orchidpharmed0 个研究点目标入组 30 人待定

概览

阶段
3 期
干预措施
未指定
疾病 / 适应症
Condition 1: Diabetes mellitus type 2. Condition 2: Transplant Kidney.
发起方
Orchidpharmed
入组人数
30
状态
已完成
最后更新
3年前

概览

简要总结

暂无简介。

注册库
who.int
开始日期
待定
结束日期
待定
最后更新
3年前
研究类型
Interventional
性别
All

研究者

发起方
Orchidpharmed

入排标准

入选标准

  • Age\>18 years old
  • Stable state of renal function for at least the last three months
  • Consent to participate in the study
  • Sustained immunosuppressive therapy for at least three months
  • Transplantation \> one year ago
  • Diabetic patient according to the criteria of the American Diabetes Association

排除标准

  • Surgery or medical conditions that affect the rate of Absorption,Distribution and Metabolism or Excretion of the drug
  • More than one transplant
  • Pregnancy or Breastfeeding
  • Allergy or Contraindications
  • Type 1 diabetes
  • Participation in any clinical study within 3 months before the initial dose
  • Frequent UTI
  • History of Alcohol use in the 12 months prior to the initial dose
  • Donating blood or Removing 400 ml of blood is required 8 weeks before the initial dose

结局指标

主要结局

未指定

相似试验